JP6272880B2 - アルポート症候群の処置方法 - Google Patents

アルポート症候群の処置方法 Download PDF

Info

Publication number
JP6272880B2
JP6272880B2 JP2015535891A JP2015535891A JP6272880B2 JP 6272880 B2 JP6272880 B2 JP 6272880B2 JP 2015535891 A JP2015535891 A JP 2015535891A JP 2015535891 A JP2015535891 A JP 2015535891A JP 6272880 B2 JP6272880 B2 JP 6272880B2
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
composition according
certain embodiments
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015535891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536301A (ja
JP2015536301A5 (https=
Inventor
ジェレミー ダフィールド
ジェレミー ダフィールド
バルクリシェン バット
バルクリシェン バット
ディードラ マッケナ
ディードラ マッケナ
Original Assignee
レグルス セラピューティクス インコーポレイテッド
レグルス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レグルス セラピューティクス インコーポレイテッド, レグルス セラピューティクス インコーポレイテッド filed Critical レグルス セラピューティクス インコーポレイテッド
Publication of JP2015536301A publication Critical patent/JP2015536301A/ja
Publication of JP2015536301A5 publication Critical patent/JP2015536301A5/ja
Application granted granted Critical
Publication of JP6272880B2 publication Critical patent/JP6272880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015535891A 2012-10-09 2013-10-08 アルポート症候群の処置方法 Active JP6272880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261711514P 2012-10-09 2012-10-09
US61/711,514 2012-10-09
US201361779137P 2013-03-13 2013-03-13
US61/779,137 2013-03-13
PCT/US2013/063884 WO2014058881A1 (en) 2012-10-09 2013-10-08 Methods for treatment of alport syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017253345A Division JP2018080190A (ja) 2012-10-09 2017-12-28 アルポート症候群の処置方法

Publications (3)

Publication Number Publication Date
JP2015536301A JP2015536301A (ja) 2015-12-21
JP2015536301A5 JP2015536301A5 (https=) 2016-12-01
JP6272880B2 true JP6272880B2 (ja) 2018-01-31

Family

ID=49382663

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015535891A Active JP6272880B2 (ja) 2012-10-09 2013-10-08 アルポート症候群の処置方法
JP2017253345A Pending JP2018080190A (ja) 2012-10-09 2017-12-28 アルポート症候群の処置方法
JP2019189071A Pending JP2020073479A (ja) 2012-10-09 2019-10-16 アルポート症候群の処置方法
JP2022083586A Pending JP2022110140A (ja) 2012-10-09 2022-05-23 アルポート症候群の処置方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017253345A Pending JP2018080190A (ja) 2012-10-09 2017-12-28 アルポート症候群の処置方法
JP2019189071A Pending JP2020073479A (ja) 2012-10-09 2019-10-16 アルポート症候群の処置方法
JP2022083586A Pending JP2022110140A (ja) 2012-10-09 2022-05-23 アルポート症候群の処置方法

Country Status (34)

Country Link
US (8) US9012423B2 (https=)
EP (2) EP3620522B1 (https=)
JP (4) JP6272880B2 (https=)
KR (4) KR20230136686A (https=)
CN (1) CN104718295B (https=)
AR (1) AR092940A1 (https=)
AU (3) AU2013329427B2 (https=)
BR (1) BR112015007709B1 (https=)
CA (1) CA2885605A1 (https=)
CL (1) CL2015000873A1 (https=)
CR (1) CR20150236A (https=)
CY (1) CY1122479T1 (https=)
DK (1) DK2906698T3 (https=)
EA (1) EA201590711A1 (https=)
ES (2) ES2960488T3 (https=)
HR (1) HRP20191948T1 (https=)
HU (1) HUE045858T2 (https=)
IL (2) IL237768B (https=)
LT (1) LT2906698T (https=)
MX (1) MX356340B (https=)
MY (1) MY183921A (https=)
NZ (1) NZ630596A (https=)
PH (1) PH12015500781A1 (https=)
PL (1) PL2906698T3 (https=)
PT (1) PT2906698T (https=)
RS (1) RS60014B1 (https=)
SG (1) SG11201502748RA (https=)
SI (1) SI2906698T1 (https=)
TN (1) TN2015000099A1 (https=)
TW (1) TWI641388B (https=)
UA (1) UA116639C2 (https=)
UY (1) UY35069A (https=)
WO (1) WO2014058881A1 (https=)
ZA (1) ZA201502087B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080190A (ja) * 2012-10-09 2018-05-24 レグルス セラピューティクス インコーポレイテッド アルポート症候群の処置方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
HUE031595T2 (en) 2011-04-25 2017-07-28 Regulus Therapeutics Inc Micro RNA Compounds s Methods for Modulating Mir-21 Activity
EA030211B1 (ru) 2012-04-25 2018-07-31 Регьюлэс Терапьютикс Инк. Соединения на основе микрорнк и способы модулирования активности mir-21
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2016014781A1 (en) * 2014-07-25 2016-01-28 Rgdi3, Inc. Collagen iv replacement
CA2958585C (en) * 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
EP3564373A4 (en) * 2016-12-28 2020-12-16 Daiichi Sankyo Company, Limited THERAPEUTIC DRUG FOR ALPORT SYNDROME
KR20190141770A (ko) * 2017-05-04 2019-12-24 사노피 알포트 증후군의 치료 방법
WO2018226880A1 (en) 2017-06-06 2018-12-13 Zymergen Inc. A htp genomic engineering platform for improving escherichia coli
WO2018226900A2 (en) 2017-06-06 2018-12-13 Zymergen Inc. A htp genomic engineering platform for improving fungal strains
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
HUE070436T2 (hu) 2017-10-23 2025-06-28 Stoke Therapeutics Inc Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
SG11202104409YA (en) 2018-10-31 2021-05-28 Zymergen Inc Multiplexed deterministic assembly of dna libraries
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
CN113728106A (zh) 2019-03-08 2021-11-30 齐默尔根公司 微生物中的迭代基因组编辑
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021189019A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
TW202413355A (zh) * 2022-05-09 2024-04-01 瑞士商卡利迪塔斯療法瑞士股份有限公司 新醫藥用途
WO2024238950A1 (en) * 2023-05-18 2024-11-21 Keros Therapeutics, Inc. Methods of using activin receptor type ii variants
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100574597B1 (ko) * 1998-05-22 2006-04-28 보이스 타운 내셔널 리서치 호스피탈 α1β1 인테그린 수용체 저해제 및 ＴＧＦ-β1 저해제의신장 질환의 치료용 용도
HUP0202048A3 (en) * 1998-05-22 2006-11-28 Boys Town Nat Res Hospital Oma Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
US20060008817A1 (en) 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP2447370B1 (en) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20050124591A1 (en) * 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US7585550B2 (en) 2004-02-02 2009-09-08 College Of William And Mary Process for modifying polymeric surfaces using deep UV irradiation
EP2290073A3 (en) 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
EP1802331A2 (en) 2004-09-08 2007-07-04 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
EP1931780B1 (en) * 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Antisense compounds having enhanced anti-microrna activity
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2007888A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
EP2208798B1 (de) 2006-10-09 2013-08-07 Medizinische Hochschule Hannover MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen
AU2007333107A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
WO2008086807A2 (en) 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
CA2691691C (en) * 2007-06-20 2013-09-24 Seth J. Baum Compositions and methods of treating chronic kidney disease
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
US8211867B2 (en) 2007-10-29 2012-07-03 Regulus Therapeutics Inc. Targeting microRNAs for the treatment of liver cancer
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
WO2009099326A1 (en) 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US20120027753A1 (en) 2009-02-26 2012-02-02 The Ohio State University MicroRNAs in Never-Smokers and Related Materials and Methods
SG176716A1 (en) 2009-06-08 2012-01-30 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
HUE031595T2 (en) 2011-04-25 2017-07-28 Regulus Therapeutics Inc Micro RNA Compounds s Methods for Modulating Mir-21 Activity
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
EA030211B1 (ru) 2012-04-25 2018-07-31 Регьюлэс Терапьютикс Инк. Соединения на основе микрорнк и способы модулирования активности mir-21
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
AU2013324716B2 (en) 2012-09-26 2019-06-13 Guandong Mijinjia Biotechnology Co., Ltd Oligomers with improved off-target profile
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080190A (ja) * 2012-10-09 2018-05-24 レグルス セラピューティクス インコーポレイテッド アルポート症候群の処置方法

Also Published As

Publication number Publication date
BR112015007709A2 (pt) 2017-08-08
AU2021269404A1 (en) 2021-12-16
AR092940A1 (es) 2015-05-06
SI2906698T1 (sl) 2019-11-29
KR20220005634A (ko) 2022-01-13
PT2906698T (pt) 2019-11-05
US9688986B2 (en) 2017-06-27
EP2906698B1 (en) 2019-07-31
CR20150236A (es) 2015-06-30
CL2015000873A1 (es) 2015-08-14
US20180298385A1 (en) 2018-10-18
PH12015500781B1 (en) 2015-06-15
CY1122479T1 (el) 2021-01-27
BR112015007709B1 (pt) 2022-05-17
IL262200A (en) 2018-11-29
IL237768B (en) 2018-10-31
KR102165189B1 (ko) 2020-10-14
HK1212378A1 (en) 2016-06-10
MY183921A (en) 2021-03-17
US20150299704A1 (en) 2015-10-22
KR102349184B1 (ko) 2022-01-07
PL2906698T3 (pl) 2020-05-18
KR20200118245A (ko) 2020-10-14
DK2906698T3 (da) 2019-11-04
TWI641388B (zh) 2018-11-21
CA2885605A1 (en) 2014-04-17
EP3620522A1 (en) 2020-03-11
HRP20191948T1 (hr) 2020-04-03
JP2022110140A (ja) 2022-07-28
EP2906698A1 (en) 2015-08-19
MX356340B (es) 2018-05-23
US20160319283A1 (en) 2016-11-03
AU2013329427B2 (en) 2019-05-02
US9359609B2 (en) 2016-06-07
US20140100263A1 (en) 2014-04-10
AU2013329427A1 (en) 2015-04-02
UA116639C2 (uk) 2018-04-25
KR20150064072A (ko) 2015-06-10
RS60014B1 (sr) 2020-04-30
US9012423B2 (en) 2015-04-21
US20240167032A1 (en) 2024-05-23
AU2019210494A1 (en) 2019-08-15
JP2020073479A (ja) 2020-05-14
NZ630596A (en) 2017-05-26
JP2018080190A (ja) 2018-05-24
EP3620522B1 (en) 2023-07-26
ES2753174T3 (es) 2020-04-07
SG11201502748RA (en) 2015-05-28
PH12015500781A1 (en) 2015-06-15
WO2014058881A1 (en) 2014-04-17
US20200283765A1 (en) 2020-09-10
ES2960488T3 (es) 2024-03-05
JP2015536301A (ja) 2015-12-21
US20170369879A1 (en) 2017-12-28
LT2906698T (lt) 2019-11-11
US9970011B2 (en) 2018-05-15
CN104718295B (zh) 2020-03-13
US20220098582A1 (en) 2022-03-31
KR20230136686A (ko) 2023-09-26
TW201420120A (zh) 2014-06-01
TN2015000099A1 (en) 2016-06-29
HUE045858T2 (hu) 2020-01-28
CN104718295A (zh) 2015-06-17
EA201590711A1 (ru) 2015-07-30
UY35069A (es) 2014-04-30
MX2015004460A (es) 2015-11-23
ZA201502087B (en) 2016-06-29

Similar Documents

Publication Publication Date Title
JP6272880B2 (ja) アルポート症候群の処置方法
JP7133553B2 (ja) 多発性嚢胞腎疾患の処置のための修飾オリゴヌクレオチド
KR20180080181A (ko) 다낭포성 신장 질환의 치료 방법
KR102780365B1 (ko) 다낭성 신장 질환의 치료 방법
HK40022692A (en) Methods for treatment of alport syndrome
HK1212378B (en) Methods for treatment of alport syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161007

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180104

R150 Certificate of patent or registration of utility model

Ref document number: 6272880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250